OnBioVC

February 2008 Summary Available

arubenstein — Sun, 27 Apr 2008 21:31:27 +0000

The OnBioVC February 2008 monthly summary is now available on the REPORTS tab (here) if reading via email or RSS reader or if on the site simply click on the tab above. Thank you.

Taligen Therapeutics, Inc.: Series B $65M

arubenstein — Sun, 27 Apr 2008 21:19:29 +0000

Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.

Arriva Pharmaceuticals, Inc.: Series ? $6M

arubenstein — Sun, 27 Apr 2008 21:17:57 +0000

Arriva Pharmaceuticals (Alameda, CA) a development stage biotechnology company focused anti-inflammatory therapies for treating respiratory diseases closed a $6M financing. Participants included Nordic Biotech and MPM Capital.

TyRx Pharma, Inc.: Series A $25M

arubenstein — Sun, 27 Apr 2008 21:14:14 +0000

TyRx Pharma (Monmouth Junction, NJ) a commercialization-stage developer of implantable drug-device combination products closed a $25M Series A financing. Participants include Clarus Ventures and Pappas Ventures.

PhaseRx, Inc.: Series A $19M

arubenstein — Sun, 27 Apr 2008 21:13:12 +0000

PhaseRx (Seattle, WA) an early-stage siRNA therapeutic company closed a $19M Series A financing. Participants include 5AM Ventures, Arch Venture Partners and Versant Ventures.

Cianna Medical, Inc.: Series A $9M

arubenstein — Sun, 27 Apr 2008 21:12:19 +0000

Cianna Medica (Aliso Viejo, CA) a brachytherapy medical device company focused on women’s health and dedicated to the innovative treatment of early-stage breast cancer closed a $9M Series A financing. Participants include BioLucent, Fog City Fund and Windamere Venture Partners.

Obalon Therapeutics, Inc.: Series A $7.7M

arubenstein — Sun, 27 Apr 2008 21:11:06 +0000

Obalon Therapeutics (San Diego, CA) a stealth mode drug startup closed on a $4.7M tranche of a $7.7M Series A financing. Participants include Domain Associates, Okapi Ventures and Phagia Technology Inc.

Adnavance Technologies, Inc.: Series B $3.6M

arubenstein — Sun, 27 Apr 2008 21:10:28 +0000

Adnavance (Canada) developer of DNA detection molecular diagnostic tests for MRSA identification closed a $3.7M Series B financing. Participants include GrowthWorks Capital, JovInvestment Management and Business Development Bank of Canada.

Vaccinex, Inc.: Series B $25M

arubenstein — Sun, 27 Apr 2008 21:09:19 +0000

Vaccinex (Rochester, NY) a research and development stage antibody platform company focused on oncology and inflammation closed a $25M Series B financing. Participants include Teva Pharmaceuticals, Pan Atlantic Bank & Trust, Biocon and Toronto Investment Group.

Affomix, Corp.: Series A $7M

arubenstein — Sun, 27 Apr 2008 21:08:17 +0000

Affomic (New Haven, CT) a development stage biotechnology company designing antibody microarrays closed a $7M Series A financing. Participants include Connecticut Innovations, Elm Street Ventures, and Four Seasons Ventures.